Novavax's Covid Vaccine Gets Emergency Use Nod For Kids Aged 12-17 In India
NDTV
Novavax last month said its vaccine was 80% effective against COVID-19 in a late-stage trial testing the shot in 2,247 teens aged 12 to 17 years.
Novavax Inc said on Tuesday its COVID-19 vaccine has got emergency-use authorization from the Drugs Controller General of India for children aged 12 to 17 years.
The authorization is a global first for the age group for the vaccine, which is manufactured and marketed in India by the Serum Institute of India under the brand name Covovax.
Novavax last month said its vaccine was 80% effective against COVID-19 in a late-stage trial testing the shot in 2,247 teens aged 12 to 17 years.
The company said on Tuesday its vaccine produced an immune response in the same age group in a mid- to late-stage study involving 460 Indian adolescents.
